Technical Stock Analysis
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), a Healthcare
sector firm, traded 698237 shares in last trading session and stock plummeted
-0.73% with closing price of $134.37 per share. Company gross margins
represents its total sales revenue minus its cost of goods sold (COGS), divided
by the total sales revenue earned by the company, expressed as a percentage.
And its good to know that the higher that percentage, the more the company
retains on each dollar of sales, to service its other costs and the debt
obligations, and Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s
gross margin stands at 93.80%.
Investment Worthy Stock or not?
For personal guess ROI is usually expressed as a percentage and is typically
used for taking any financial decisions, for the purpose of comparing a Jazz
Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s profitability or to
compare the efficiency of different investments, hence, JAZZ return on
investment (ROI) is 12.20%.
52-Week Range
52-Week Range are valuable stats for watching Jazz Pharmaceuticals plc –
Ordinary Shares (NASDAQ:JAZZ)’s past year fluctuation as that gives investors
an idea of how much the security has moved in the last year and whether it is
trading near the top, middle or bottom of the range. Jazz Pharmaceuticals plc –
Ordinary Shares (NASDAQ:JAZZ)’s stock value has moved between $113.87 – 184.07
in last one year.
Analyst’s Views
Analysts mean target price for Jazz Pharmaceuticals plc – Ordinary Shares
(NASDAQ:JAZZ) is $172.67 while analysts mean recommendation is 1.90.
Stock Performance
Its weekly performance is 3.02% while year to date (YTD) performance is 8.40%.
EPS Growth
Earnings per share growth is defined as the percentage change in normalised
earnings per share over the previous 12 month period to the latest year end. It
gives a good picture of the rate at which a company has grown its
profitability. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s EPS
growth this year is 34.60%. For best decision making investors should look at
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s EPS growth for next
year stands at 16.59%.
